Barbara Jane O’Brien, MD

Articles by Barbara Jane O’Brien, MD

Dr O’Brien on Tucatinib Plus Trastuzumab/Capecitabine for Leptomeningeal Metastases in HER2+ Breast Cancer

August 22nd 2024

Barbara Jane O’Brien, MD, discusses tucatinib plus trastuzumab and capecitabine for leptomeningeal metastases in HER2-positive breast cancer.

Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Dr O'Brien on Breast Cancer Research in Patients With HER2+ Brain Metastases

ByBarbara Jane O’Brien, MD

July 18th 2024

Barbara Jane O’Brien, MD, discusses expanding clinical trial enrollment criteria to include patients with HER2-positive breast cancer brain metastases.

Barbara Jane O’Brien, MD

Articles by Barbara Jane O’Brien, MD

Dr O’Brien on Tucatinib Plus Trastuzumab/Capecitabine for Leptomeningeal Metastases in HER2+ Breast Cancer

Dr O'Brien on Breast Cancer Research in Patients With HER2+ Brain Metastases

Latest Updated Articles

Trending on OncLive

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma

Oncology Fellows Highlights 2025 ESMO Fellowship Winners